Effect of canarypox virus (ALVAC)-mediated cytokine expression on murine prostate tumor growth

Journal of the National Cancer Institute

Volumn 89, Issue 6, 1997, Pages 428-436

  Kawakita, Mutsushi ^a   Rao, Ganesh S ^a   Ritchey, Julie K ^a   Ornstein, David K ^a   Hudson, M'Liss A ^a   Tartaglia, James ^b   Paoletti, Enzo ^b   Humphrey, Peter A ^a   Harmon, Taz J ^a   Ratliff, Timothy L ^a,c  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Virogenetics Corporation   (United States)

^c UNIVERSITY OF IOWA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; DNA SEQUENCE; GENE EXPRESSION REGULATION; GROWTH INHIBITION; IMMUNOPRECIPITATION; MOUSE; NONHUMAN; POXVIRUS; PROSTATE TUMOR; T LYMPHOCYTE ACTIVATION; TUMOR GROWTH; VACCINIA VIRUS;

EID: 17944404215     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/89.6.428     Document Type: Article

References (39)

1. Pardoll DM. Cancer vaccines. Immunol Today 1993;14:310-6.
2. Bannerji R, Arroyo CD, Cordon-Cardo C, Gilboa E. The role of IL-2 secreted from genetically modified tumor cells in the establishment of antitumor immunity. J Immunol 1994;152:2324-32.
3. Porgador A, Bannerji R, Watanabe Y, Feldman M, Gilboa E, Eisenbach L. Antimetastatic vaccination of tumor-bearing mice with two types of IFN-γ gene-inserted tumor cells. J Immunol 1993;150:1458-70.
4. Moss B. Vaccinia virus: a tool for research and vaccine development. Science 1991;252:1662-7.
5. Peplinski GR, Tsung K, Meko JB, Norton JA. In vivo gene therapy of a murine pancreas tumor with recombinant vaccinia virus encoding human interleukin-1 beta. Surgery 1995;118:185-90.
6. Bash JA. Recombinant vaccinia interleukin-2-infected tumor cell vaccines in immunotherapy of murine colon adenocarcinoma. J Immunother 1993;14:269-72.
7. Meko JB, Yim JH, Tsung K, Norton JA. High cytokine production and effective antitumor activity of a recombinant vaccinia virus encoding murine interleukin 12. Cancer Res 1995;55:4765-70.
8. Hodge JW, Abrams S, Schlom J, Kantor JA. Induction of antitumor immunity by recombinant vaccinia viruses expressing B7-1 or B7-2 costimulatory molecules. Cancer Res 1994;54:5552-5.
9. Bronte V, Tsung K, Rao JB, Chen PW, Wang M, Rosenberg SA, et al. IL-2 enhances the function of recombinant poxvirus-based vaccines in the treatment of established pulmonary metastases. J Immunol 1995; 154:5282-92.
10. McCabe BJ, Irvine KR, Nishimura MI, Yang JC, Spiess PJ, Shulman EP, et al. Minimal determinant expressed by a recombinant vaccinia virus elicits therapeutic antitumor cytolytic T lymphocyte responses. Cancer Res 1995;55:1741-7.
11. Lane JM, Ruben FL, Neff JM, Millar JD. Complications of smallpox vaccination, 1968. N Engl J Med 1969;281:1201-8.
12. Tartaglia J, Perkus ME, Taylor J, Norton EK, Audonnet JC, Cox WI, et al. NYVAC: a highly attenuated strain of vaccinia virus. Virology 1992;188:217-32.
13. Tartaglia J, Taylor J, Cox WI, Audonnet JC, Perkus ME, Paoletti E. Novel poxvirus strains as research tools and vaccine vectors. In: Koff WC, Wong-Staal F, Kennedy RC, editors. AIDS research reviews. Vol. 3. 1st ed. New York: Marcel Dekker, 1993:361-78.
14. Taylor J, Trimarchi C, Weinberg R, Languet B, Guillemin F, Desmettre P, et al. Efficacy studies on a canarypox-rabies recombinant virus. Vaccine 1991;9:190-3.
15. Cadoz M, Strady A, Meignier B, Taylor J, Tartaglia J, Paoletti E, et al. Immunisation with canarypox virus expressing rabies glycoprotein. Lancet 1992;339:1429-32.
16. Taylor J, Weinberg R, Tartaglia J, Richardson C, Alkhatib G, Briedis D, et al. Nonreplicating viral vectors as potential vaccines: recombinant canary-pox virus expressing measles virus fusion (F) and hemagglutinin (HA) glycoproteins. Virology 1992;187:321-8.
17. Tartaglia J, Jarrett O, Neil JC, Desmettre P, Paoletti E. Protection of cats against feline leukemia virus by vaccination with a canarypox virus recombinant, ALVAC-FL. J Virol 1993;67:2370-5.
18. Cox WI, Tartaglia J, Paoletti E. Induction of cytotoxic T lymphocytes by recombinant canarypox (ALVAC) and attenuated vaccinia (NYVAC) viruses expressing the HIV-1 envelope glycoprotein. Virology 1993;195:845-50.
19. Pialoux G, Excler JL, Riviere Y, Gonzalez-Canali G, Feuilie V, Coulaud P, et al. A prime-boost approach to HIV preventive vaccine using a recombinant canarypox virus expressing glycoprotein 160 (MN) followed by a recombinant glycoprotein 160 (MN/LAI). The AGIS Group, and l'Agence Nationale de Recherche sur le SIDA [published erratum appears in AIDS Res Hum Retroviruses 1995;11:875]. AIDS Res Hum Retroviruses 1995;11:373-81.
20. Baley PA, Yoshida K, Qian W, Sehgal I, Thompson TC. Progression to androgen insensitivity in a novel in vitro mouse model for prostate cancer. J Steroid Biochem Mol Biol 1995;52:403-13.
21. Thompson TC, Southgate J, Kitchener G, Land H. Multistage carcinogenesis induced by ras and myc oncogenes in a reconstituted organ. Cell 1989;56:917-30.
22. Coplen DE, Brown EJ, McGarr J, Ratliff TL. Characterization of fibronectin attachment by a human transitional cell carcinoma line, T24. J Urol 1991;145:1312-5.
23. Russell JH, Rush BJ, Abrams SI, Wang R. Sensitivity of T cells to anti-CD3-stimulated suicide is independent of functional phenotype. Eur J Immunol 1992;22:1655-8.
24. Scudiero DA, Shoemaker RH, Paull KD, Monks A, Tierney S, Nofziger TH, et al. Evaluation of a soluble tetrazolium/formazan assay for cell growth and drug sensitivity in culture using human and other tumor cell lines. Cancer Res 1988;48:4827-33.
25. Evans CH, Heinbaugh JA. Lymphotoxin cytotoxicity, a combination of cytolytic and cytostatic cellular responses. Immunopharmacology 1981;3:347-59.
26. Fedarko NS, D'Avis P, Frazier CR, Burrill MJ, Fergusson V, Tayback M, et al. Cell proliferation of human fibroblasts and osteoblasts in osteogenesis imperfecta: influence of age. J Bone Miner Res 1995;10:1705-12.
27. Perkus ME, Tartaglia J, Paoletti E. Poxvirus-based vaccine candidates for cancer, AIDS, and other infectious diseases. J Leukoc Biol 1995;58:1-13.
28. + T cells. ICAM-1 or B7-1 can costimulate naive CD4T cell activation but both are required for optimum response. J Immunol 1995;155:45-57.
29. Lanier LL, O'Fallon S, Somoza C, Phillips JH, Linsley PS, Okumura K, et al. CD80 (B7) and CD86 (B70) provide similar costimulatory signals for T cell proliferation, cytokine production, and generation of CTL. J Immunol 1995;154:97-105.
30. Guerder S, Carding SR, Flavell RA. B7 costimulation is necessary for the activation of the lytic function in cytotoxic T lymphocyte precursors. J Immunol 1995;155:5167-74.
31. Chen L, McGowan P, Ashe S, Johnston J, Li Y, Hellstrom I, et al. Tumor immunogenicity determines the effect of B7 costimulation on T cell-mediated tumor immunity. J Exp Med 1994;179:523-32.
32. Wu TC, Huang AY, Jaffee EM, Levitsky HI, Pardoll DM. A reassessment of the role of B7-1 expression in tumor rejection. J Exp Med 1995;182:1415-21.
33. Asher AL, Mule JJ, Kasid A, Restifo NP, Salo JC, Reichert CM, et al. Murine tumor cells transduced with the gene for tumor necrosis factor-α. Evidence for paracrine immune effects of tumor necrosis factor against tumors. J Immunol 1991;146:3227-34.
34. Allione A, Consalvo M, Nanni P, Lollini PL, Cavallo F, Giovarelli M, et al. Immunizing and curative potential of replicating and nonreplicating murine mammary adenocarcinoma cells engineered with interleukin (IL)-2, IL-4, IL-6, IL-7, IL-10, tumor necrosis factor α, granulocyte-macrophage colony-stimulating factor, and γ-interferon gene or admixed with conventional adjuvants. Cancer Res 1994;54:6022-6.
35. Hock H, Dorsch M, Kunzendorf U, Qin Z, Diamantstein T, Blankenstein T. Mechanisms of rejection induced by tumor cell-targeted gene transfer of interleukin 2, interleukin 4, interleukin 7, tumor necrosis factor, or interferon γ. Proc Natl Acad Sci U S A 1993;90:2774-8.
36. Rosenthal FM, Cronin K, Bannerji R, Golde DW, Gansbacher B. Augmentation of antitumor immunity by tumor cells transduced with a retroviral vector carrying the interleukin-2 and interferon-γ cDNAs. Blood 1994;83:1289-98.
37. Dranoff G, Jaffee E, Lazenby A, Golumbek P, Levitsky H, Brose K, et al. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci U S A 1993;90:3539-43.
38. Zatloukal K, Schneeberger A, Berger M, Schmidt W, Koszik F, Kutil R, et al. Elicitation of a systemic and protective anti-melanoma immune response by an IL-2-based vaccine. Assessment of critical cellular and molecular parameters. J Immunol 1995;154:3406-19.
39. Lee SS, Eisenlohr LC, McCue PA, Mastrangelo MJ, Lattime EC. Intravesical gene therapy: in vivo gene transfer using recombinant vaccinia virus vectors. Cancer Res 1994;54:3325-8.